Resverlogix Announces a Corporate Update Conference Call & Webcast

Calgary, Alberta (ots/PRNewswire) -

TSX Exchange Symbol: RVX

Resverlogix Corp. today announced they will be hosting a
corporate update conference call and webcast with Q&A on September
3rd at 11 am MDT.

Details for the conference call and webcast are as follows:

Link to webcast:
http://services.choruscall.ca/links/resverlogix130905.html

Dial in numbers:

Canada & USA Toll Free Dial In: 1-800-319-4610 Outside of Canada &
USA call: +1-604-638-5340

About RVX-208

RVX-208 is a first-in-class small molecule that inhibits BET
bromodomains. RVX-208 functions by removing atherosclerotic plaque
via reverse cholesterol transport (RCT), the natural process through
which atherosclerotic plaque is transported out of the arteries and
removed from the body by the liver. RVX-208 increases production of
Apolipoprotein A-I (ApoA-I), the key building block of functional
high-density lipoprotein (HDL) particles and the type required for
RCT. These newly produced, functional HDL particles are flat and
empty and can efficiently remove plaque and stabilize or reverse
atherosclerotic disease. ApoA-I may also exert beneficial effects in
Alzheimer's disease and Diabetes Mellitus.

About Resverlogix

Resverlogix Corp. is a clinical stage biotechnology company
developing compounds involving ApoA-I production. RVX-208 is a
first-in-class small molecule in development for the treatment of
diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer's
disease. RVX-208 is the first BET bromodomain inhibitor in clinical
trials. Resverlogix's common shares trade on the Toronto Stock
Exchange . For further information please visit
http://www.resverlogix.com. We can be followed on our blog at
http://www.resverlogix.com/blog.

This news release may contain certain forward-looking information
as defined under applicable Canadian securities legislation, that are
not based on historical fact, including without limitation statements
containing the words "believes", "anticipates", "plans", "intends",
"will", "should", "expects", "continue", "estimate", "forecasts" and
other similar expressions. In particular, this news release includes
forward looking information relating to research and development
activities and the potential role of RVX-208 in the treatment of
diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer's
disease. Our actual results, events or developments could be
materially different from those expressed or implied by these
forward-looking statements. We can give no assurance that any of the
events or expectations will occur or be realized. By their nature,
forward-looking statements are subject to numerous assumptions and
risk factors including those discussed in our Annual Information Form
and most recent MD&A which are incorporated herein by reference and
are available through SEDAR at http://www.sedar.com. The
forward-looking statements contained in this news release are
expressly qualified by this cautionary statement and are made as of
the date hereof. The Company disclaims any intention and has no
obligation or responsibility, except as required by law, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.

Company Contacts:

Donald J. McCaffrey
President and CEO
Resverlogix Corp.
Phone: +1-403-254-9252
Email: don@resverlogix.com
(RVX.)

Kenneth Lebioda
SVP Business & Corporate Development
Resverlogix Corp.
Phone: +1-403-254-9252
Email: ken@resverlogix.com

ots Originaltext: Resverlogix Corp.
Im Internet recherchierbar: http://www.presseportal.de